Unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics


CytomX Therapeutics (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc.


Year Invested: 2010
Location: South San Francisco, Calif.
Visit: www.cytomx.com

Recent News

November 9, 2018
CytomX Therapeutics Presents CX-072 Clinical Translational Data at 2018 SITC Annual Meeting

November 7, 2018
CytomX to Present at the Jefferies 2018 London Healthcare Conference

November 6, 2018
CytomX Therapeutics Announces CX-072 Clinical Presentations at 2018 SITC Annual Meeting

Read More News

Associated Team Members

Neil Exter
Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner